Zapped out.

Radiation of prostate cancer oligomets along with the primary prostate tumor is pretty well established at this point. Here is a small prospective phase 2 trial of 29 men receiving external beam radiation to all sites of oligomets, including the primary tumor when not previously treated. Roughly half of mets were de novo and half recurrent, and median progression-free survival for both was nearly 2 years. Numbers were small, but a stand-out median progression-free survival of nearly 6 years was seen among the 8 patients with lymph node-only disease. Finally, at a median follow-up of 10 years, 17 (59%) patients still had local control of all treated sites. | Hao, Int J Radiat Oncol Biol Phys 2022